dm+d

Unassigned

New Medicines

Information

New molecular entity
Chengdu Kanghong Biotech
Chengdu Kanghong Biotech

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Recombinant human VEGF receptor-Fc fusion protein. Inhibits VEGF-A,B and C and placental growth factor (P1GF)[1-4]
The estimated prevalence of late AMD in the UK is 4.8% of those over 65 years of age and 12.2% of those aged 80 years or more [5].
Neovascular (wet) age-related macular degeneration
Intravitreal

Evidence based evaluations